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Endocrine therapy for breast cancer is arguably the first
effective systemic treatment for human cancer and is the first
targeted therapy [1]. Similar to many recently developed
targeted therapies for breast and other malignancies,
hormonal treatments for breast cancer include ligand
deprivation (oestrogen depletion) and receptor agonism and
antagonism. Given the safety and efficacy of the established
hormonal options, the growing challenge that we confront
with the development of an increasing number of novel
targeted agents is whether these can be combined rationally,
and if so then how, to improve patient outcomes while avoiding
unwarranted toxicities.
Historically, the usual argument for combining therapeutics
was the belief that two or more treatments would attack a
malignant cell in an additive or synergistic manner, thereby
improving outcomes [2]. Most combinations such as multi-
agent chemotherapy regimens (for instance, cyclophos-
phamide, methotrexate, and 5-fluouracil [CMF]) or chemo-
therapy with concurrent hormone therapy were empiric rather
than truly translational and have not been shown to provide
consistent advantage over sequential applications of optimal
single agents and, in some cases, have been associated only
with increased toxicities [3]. In breast cancer this paradigm
was changed most clearly with the development of trastuzu-
mab, which included translation of preclinical models into a
rational human trial demonstrating improved survival com-
pared with the sequential application of the same agents
(chemotherapy and trastuzumab) [4,5]. With increased
understanding of the roles not only of HER2 but also of the
other members of the human epidermal growth factor
receptor family (HER1, HER3, and HER4), rationale for
specific combinations of hormonal therapies and signal
transduction inhibitors (antibodies, tyrosine kinase inhibitors,
and so on) has emerged [6]. However, a key challenge is to
identify the most promising of these combinations for testing
in a time of limited resources while simultaneously remaining
sensitive to the risks to cost-effectiveness and quality of life
that some combinations may represent. Because hormone
therapy for breast cancer is generally well tolerated, any
negative impact on patient quality of life will have to be
justified by meaningful improvements in outcome.
A first consideration could be the addition of agents that
inhibit or reverse the development of hormone agent specific
resistance. One model for such resistance suggests that
bidirectional crosstalk between the oestrogen receptor and
HER2 converts tamoxifen into an agonist [7]. This suggests
that anti-HER2 therapies may be useful in preventing or
reversing tamoxifen resistance specifically and hormone
resistance in general. Based on such models, trastuzumab
has been combined with modern hormone therapies in a
variety of trials, including a large phase 3 study of the
aromatase inhibitor anastrozole [8]. This randomized trial
illustrates the challenges of such combinations, because
although it demonstrated a statistically significant improve-
ment in progression-free survival, this was not associated
with improved overall survival and the clinical outcomes
remained disappointing. Furthermore, the study left un-
resolved the potential value of sequential use of trastuzumab
after progression on the aromatase inhibitor. Nevertheless,
clinical trials are appropriately continuing in this vein,
including, for example, fulvestrant with trastuzumab.
More recently, oral tyrosine kinase inhibitors, with varying
degrees not only of anti-HER2 effectiveness but also of anti-
HER1 activity, have reached the clinic for breast cancer, led
first by lapatinib [9]. The rationale for building combinations
with hormonal agents is perhaps increased for these new
drugs compared with trastuzumab because of their relative
pan-HER inhibition. The Cancer and Leukaemia Group B has
recently launched study 40302, a randomized double-blind
placebo controlled trial of fulvestrant (a selective oestrogen
receptor downregulator) alone or with lapatinib. Related trials
including aromatase inhibition with or without gefitinib have
not yet demonstrated clear clinical advantages, but they have
provided tumour specimens that allow us to try to elucidate
where and how such combinations might be effective
[10,11]. Correlative science studies such as these are an
important aspect of this generation of trials because they
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Among many enlightening examples of the value of this
approach are the studies of cyclo-oxygenase (COX)-2
inhibitors. Preclinical studies suggested a role for these
agents in a variety of tumour settings, including hormone-
responsive breast cancer. Based on this, a factorial design
was incorporated into the National Cancer Institute of
Cancada (NCIC) MA-27 trial comparing anastrozole with
exemestane, such that patients were also randomized for the
use of celecoxib. After the potential toxicities of celecoxib in
the general population were reported, this randomization was
dropped. However, COX inhibition, both COX-1 and COX-2,
remains an important area for clinical research in breast
cancer for the following reasons. First, COX inhibitors (aspirin
and nonsteroidal anti-inflammatory agents) are widely used in
the general population. Second, COX-2 expression is
associated with HER2 overexpression. Finally, there is a
connection between COX-2 and aromatase activity [12,13].
To better understand this latter connection, a preoperative or
so-called ‘window’ trial allows for a brief exposure to
celecoxib with paired specimen collection to determine
whether the target is in fact inhibited in breast cancer in vivo,
accompanied by the predicted downstream effects. Such
trials will gain importance as we attempt to identify the best of
the increasing number of new targeted agents for clinical
testing. Validation of targeting in vivo should be a component
of new drug development whenever possible, but will require
dedicated collaborative efforts supported by adequate
resources.
Angiogenesis has long been recognized as a critical step in
the development of human cancer and inhibitors, both
antibody based (bevacizumab) and in the form of oral tyrosine
kinase inhibitors (for instance, sunitinib, sorafenib and others),
are now broadly available for clinical testing [14]. Animal
models demonstrating the role of oestrogens in stimulating
angiogenesis provide the foundation of testing combinations
of anti-angiogenics with hormone therapy in breast cancer
[15-17]. Because the first narrowly targeted anti-angiogenic
monoclonal antibody, bevacizumab, has demonstrated broad
antitumour activity accompanied by a novel toxicity profile, a
phase 2 study of this drug combined with an aromatase
inhibitor was conducted to establish safety in preparation for
a phase 3 trial [18]. The latter study is now set to launch in
metastatic breast cancer, as are several similar studies
utilizing vascular endothelial growth factor receptor tyrosine
kinase inhibitors. If the toxicity of these combinations is
acceptable in large numbers of patients, then such
combinations could represent an important improvement over
conventional single agent hormonal approaches.
Clearly, we are at the beginning of a new era of hormone
therapy trials. Instead of continuing only to develop novel
hormone therapies or ‘better’ versions of existing agents, we
are instead asking biological questions such as how anti-HER
agents with  demonstrated effectiveness combined in
preclinical models with hormonal interventions will fare in the
clinic. We are asking as well about the potential efficacy of
inhibitors of downstream signalling mediators (for example,
mammalian target of rapamycin [mTOR] inhibition) and entirely
novel targeted therapies focused not on the tumour per se but
on the stroma and supporting tissues (anti-angiogenic
agents). These studies should provide more biological
information than the empirical studies of yesteryear and we
should view the results critically, making certain that whatever
quantitative benefits we observe are clinically justified.
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